The CHMP recommended perioperative pembrolizumab plus enfortumab vedotin for resectable muscle-invasive bladder cancer.
Related to this article
The CHMP recommended approval of adjuvant T-DXd for HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy.
CHMP has recommended EU marketing authorization for relacorilant combined with nab-paclitaxel in platinum-resistant ovarian cancer.
The positive CHMP opinion for teclistamab in second- and later-line relapsed/refractory multiple myeloma is supported by MajesTEC-9 data.
CHMP offerred a positive opinion supporting extension of melflufen to third-line, lenalidomide-refractory multiple myeloma.
Japan approved T-DXd plus pertuzumab for HER2-positive disease and Dato-DXd for triple-negative disease in first-line metastatic breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
Zipalertinib + Chemotherapy Extends PFS by 6 Months in Frontline EGFR Exon 20 Insertion–Positive NSCLC
2
FDA Grants Breakthrough Therapy Designation to First-Line Daraxonrasib Plus Chemo in mPDAC
3
Updated NCCN Guidelines Feature Additional MRD Recommendations in Multiple Myeloma
4
FDA Clears sNDA for Taletrectinib With Updated DOR Data in ROS1+ NSCLC
5